Home / Business and Economy / Pfizer Soars on mRNA Cancer Trial Hopes
Pfizer Soars on mRNA Cancer Trial Hopes
20 Aug
Summary
- Pfizer shares rose 3.8% due to positive cancer trial results from peers.
- Merck and Moderna's mRNA cancer treatment showed improved survival rates.
- The drug, combined with Keytruda, met its primary goal in a Phase 3 trial.
Pfizer's shares saw a notable increase of 3.8% during the afternoon session on August 20, 2026. This surge was largely attributed to positive clinical trial outcomes reported by peer companies Merck and Moderna regarding an mRNA cancer treatment. The market's reaction indicates that investors found this news to be significant for the pharmaceutical sector.
The groundbreaking Phase 3 clinical trial involved 1,137 patients and focused on an mRNA cancer treatment in combination with the drug Keytruda. The study successfully met its primary objective, showing a statistically significant improvement in recurrence-free survival when compared to patients treated with Keytruda alone. This success has generated positive sentiment across the pharmaceutical industry.
Earlier in 2026, Pfizer also made headlines with a significant agreement concerning prescription drug prices in the U.S. This pact included 'most-favored-nation' pricing for Medicaid programs and offered substantial discounts on medicines through a new government website. In return, Pfizer secured a three-year grace period from potential tariffs, an arrangement viewed by the market as a way to avert stricter legislation.
As of the reporting date, Pfizer's stock is up 12% year-to-date and trading near its 52-week high. However, a five-year investment perspective reveals a different story, with a $1,000 investment five years ago now valued at $577.66.
